SYNDAX PHARMACEUTICALS INCSNDX
ASignal's systematic analysis rates SNDX as Bearish.
Reflects the latest available analysis · analyzed Sep 12, 2026
The case on SNDX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong year-over-year revenue growth (91.8%)
- High cash position relative to debt (current ratio 6.77x)
- RSI near oversold territory (36.94), potential for rebound
- Negative MACD and declining momentum
- Price trading below key moving averages (SMA20, SMA50)
- Negative gross, operating, and net margins
- Negative free cash flow and operating cash flow
- High debt-to-equity ratio (39.03x)
- Extremely high price-to-book ratio (107.57x)
See the full verdict on SNDX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes SNDX
Most investors never get a second opinion, let alone several. ASignal runs SNDX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.